Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash & Equivalents (2023 - 2025)

CG Oncology filings provide 3 years of Cash & Equivalents readings, the most recent being $32.5 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 87.36% to $32.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.5 million, a 87.36% decrease, with the full-year FY2025 number at $32.5 million, down 87.36% from a year prior.
  • Cash & Equivalents hit $32.5 million in Q4 2025 for CG Oncology, down from $45.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $257.1 million in Q4 2024 to a low of $8.3 million in Q4 2023.
  • Median Cash & Equivalents over the past 3 years was $41.5 million (2025), compared with a mean of $60.6 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 3009.94% in 2024 and later tumbled 87.36% in 2025.
  • CG Oncology's Cash & Equivalents stood at $8.3 million in 2023, then skyrocketed by 3009.94% to $257.1 million in 2024, then tumbled by 87.36% to $32.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $32.5 million (Q4 2025), $45.1 million (Q3 2025), and $14.6 million (Q2 2025) per Business Quant data.